Welcome to our dedicated page for Prelude Therapeutics Incorporated news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics Incorporated stock.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies targeting key mechanisms in cancers with high unmet needs. Founded in 2016 and headquartered in Wilmington, Delaware, the company's mission is to deliver precision oncology treatments that can address the critical pathways in cancer cells.
Prelude's robust pipeline includes several promising drug candidates currently in clinical development:
- PRT543: This candidate is in Phase 1 clinical trials targeting select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies.
- PRT811: Also in Phase 1 trials, PRT811 focuses on solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas.
- PRT1419: A potent and selective inhibitor of the anti-apoptotic protein MCL1, which is undergoing clinical evaluation for its efficacy and safety in cancer treatment.
- PRT2527: This highly selective CDK9 inhibitor demonstrates substantial potential in treating solid and hematological malignancies and aims to minimize off-target toxicities.
- PRT3645: A next-generation CDK4/6 inhibitor that shows promise for better safety, tolerability, and efficacy in various cancers beyond breast cancer.
- PRT3789: A first-in-class SMARCA2 protein degrader targeting cancers with SMARCA4 mutations.
In recent developments, Prelude has extended its cash runway into 2026 following a successful public offering, raising approximately $113 million in gross proceeds. Their strategic collaboration with AbCellera aims to co-develop innovative antibody drug conjugate therapies, combining AbCellera's antibody discovery platform with Prelude's expertise in medicinal chemistry and drug development.
Prelude's financial strength is evident with cash, cash equivalents, and marketable securities totaling $255 million as of June 30, 2023. Their focused approach on advancing their pipeline and making critical strategic decisions is supported by clinical data showing promising efficacy and safety profiles for their drug candidates, such as PRT2527 and PRT1419. The company's commitment to addressing cancers with high unmet needs positions it as a significant player in precision oncology.
For more detailed information and the latest updates on Prelude Therapeutics' research advancements, financial performance, and strategic initiatives, visit their official website and follow them on LinkedIn and Twitter.
Prelude Therapeutics Inc. (NASDAQ: PRLD) announced that CEO Kris Vaddi, PhD, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET. A live webcast can be accessed through the company's Investors page, with a replay available afterwards.
Prelude is a clinical-stage precision oncology company developing innovative treatments targeting critical cancer cell pathways. Their candidates include PRT543, PRT811, PRT1419, and PRT2527, focusing on various malignancies.
Prelude Therapeutics Inc. (Nasdaq: PRLD) announced that CEO Kris Vaddi, PhD, will present at the H.C Wainwright BioConnect Virtual Conference from January 10-13, 2022. The prerecorded presentation will be available on January 10, 2022, at 7:00 am ET on the company's Investors page. Prelude is a clinical-stage precision oncology company focusing on developing innovative cancer treatments, including PRMT5 inhibitors and MCL1 inhibitors in Phase 1 development. The company is advancing several pipelines aimed at targeting critical cancer cell pathways.
Prelude Therapeutics Inc. (Nasdaq: PRLD) announced that CEO Kris Vaddi, PhD, will speak at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 9:15 am ET. A live webcast and replay will be available on Prelude's 'Investors' page. The company focuses on developing precision oncology molecules targeting cancer pathways. Its candidates include PRT543 and PRT811 for solid tumors, CNS cancers, and myeloid malignancies, along with PRT1419 and PRT2527 for hematologic malignancies and solid tumors. Other promising projects are also in the pipeline.
Prelude Therapeutics (Nasdaq: PRLD) reported third-quarter 2021 financial results, revealing a net loss of $30.7 million, or $0.66 per share, compared to a $16.8 million loss in Q3 2020. The company holds a strong cash position of $320.9 million to support its clinical pipeline. Notable updates include favorable data from Phase 1 trials for PRMT5 inhibitors PRT543 and PRT811, which showed good tolerability and preliminary clinical activity. Additionally, PRT2527's IND was cleared by the FDA, with a Phase 1 trial anticipated by year-end.
Prelude Therapeutics announced that the FDA has accepted its IND application for PRT2527, a selective CDK9 inhibitor. A Phase 1 clinical trial is expected to begin by year-end, targeting solid tumors like sarcoma and breast cancer. Preclinical studies show PRT2527 effectively reduces MYC and MCL1 protein levels, hinting at promising efficacy and safety. Prelude's CEO expressed confidence in its oncology development pipeline, aiming to provide new treatment options for challenging cancers.
Prelude Therapeutics (Nasdaq: PRLD) recently announced promising data from its Phase 1 trials of oral PRMT5 inhibitors PRT543 and PRT811, which showed favorable safety profiles and preliminary clinical activity with durable responses in various tumors. Specifically, PRT543 achieved a 69% reduction in serum sDMA and demonstrated a durable complete response in a patient with HRD+ ovarian cancer. PRT811 exhibited an 83% reduction in serum sDMA, with notable responses in patients with high-grade gliomas and uveal melanoma. Additionally, preclinical studies indicated PRT2527's efficacy in hematological malignancies.
Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology firm, announced its participation in two virtual investor conferences. The first will be at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 11:45 a.m. ET, featuring a fireside chat. The second event is at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET, with a corporate presentation. Live webcasts are available on the company's website and will be replayed for a limited time.
Prelude Therapeutics (Nasdaq: PRLD) reported a net loss of $26.9M for Q2 2021, equating to $0.58 per share, a significant increase from a net loss of $11.4M, or $5.50 per share, in Q2 2020. The company has $343.1M in cash for ongoing clinical trials, including Phase 1 studies of PRT543, PRT811, and PRT1419. Upcoming milestones include data presentations at the AACR-NCI-EORTC Annual Meeting. R&D expenses rose to $22.4M, driven by increased clinical research costs, while G&A expenses rose to $5.5M due to personnel growth and professional fees.
Prelude Therapeutics (Nasdaq: PRLD) appointed Martin Babler to its Board of Directors, bringing over 25 years of biotech experience, including his role as CEO of Principia Biopharma until its acquisition in 2020. Mr. Babler will also serve on the Audit Committee. CEO Kris Vaddi emphasized the value of his expertise in driving the company's pipeline of cancer therapies. Prelude focuses on precision oncology, with candidates like PRT543 and PRT811 in clinical trials targeting significant cancer unmet needs.
Prelude Therapeutics (Nasdaq: PRLD) announced participation in two virtual investor conferences: the 42nd Annual Goldman Sachs Global Healthcare Conference with a fireside chat on June 9, 2021, at 8:00 a.m. ET, and the JMP Securities Life Sciences Conference on June 16, 2021, at 10:00 a.m. ET. Live webcasts will be available on the company's website, with replays for a limited time. Prelude focuses on precision oncology with notable candidates like PRT543 for advanced solid tumors and PRT811 for glioblastoma.
FAQ
What is the current stock price of Prelude Therapeutics Incorporated (PRLD)?
What is the market cap of Prelude Therapeutics Incorporated (PRLD)?
What does Prelude Therapeutics Incorporated specialize in?
Where is Prelude Therapeutics Incorporated based?
What are some key drug candidates in Prelude Therapeutics' pipeline?
What is PRT2527?
What recent financial achievement has Prelude Therapeutics reported?
Who has Prelude Therapeutics partnered with for drug development?
What is PRT3645?
What is the focus of PRT3789?
What are the financial resources available to Prelude Therapeutics?
Where can I find more information about Prelude Therapeutics?
